Vaccines
Moderna tapped Jorge Gomez to take over the role of chief financial officer next month upon the retirement of David Meline, the current company CFO.
GeoVax is conducting two Phase II COVID-19 vaccine clinical trials with its GEO-CMO4S1 vaccine. One of the trials is among immunocompromised patients.
Global health officials are monitoring COVID-19 cases with an eye to identifying the emergence of new, potentially more deadly or more infectious variants. Read on for more details.
Merck strengthened its HPV vaccines manufacturing capacity with the expansion of its facility in Elkton, Virginia. Also, an additional 150 new jobs are created.
Two companies in India have halted vaccine manufacturing, which could be a sign that the pandemic may be coming to an end. For that and more COVID-19 news, continue reading.
The FDA requested additional data analyses from the pediatric studies that Merck stated it has submitted. The final decision is expected on July 1, 2022.
Although the data suggests the vaccines are extremely effective and generally safe, analysis is still coming in about adverse events as well as effectiveness in specific patient populations.
Seattle-based Icosavax’s stock plunged 50% after the company reported topline interim data from its ongoing Phase I/II COVID-19 vaccine trial.
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
Researchers at Albert Einstein College of Medicine have cleverly developed a vaccine for pancreatic cancer by using the adaptive immunity already present in nearly all of the global population.
PRESS RELEASES